Search

Search Constraints

You searched for: Author/Creator Haymaker, Cara

Search Results

11. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016. (16th November 2016)

12. 75 Generalizability of potential biomarkers of response to CTLA-4 and PD-1 blockade therapy in cancer. (10th December 2020)

13. 8 Immune correlates associated with clinical outcomes in patients with advanced malignancies treated with avelumab and OX40 agonist. (10th December 2020)

14. 8 Immune correlates associated with clinical outcomes in patients with advanced malignancies treated with avelumab and OX40 agonist. (9th November 2020)

15. A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. Issue 1 (20th September 2016)

16. A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. Issue 1 (December 2016)

17. A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. Issue 1 (December 2016)

18. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Issue 7 (19th July 2021)

19. Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity. (7th November 2013)

20. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. (3rd March 2016)